{"id":"NCT02813694","sponsor":"Nabriva Therapeutics AG","briefTitle":"Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia","officialTitle":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08","primaryCompletion":"2018-01","completion":"2018-01","firstPosted":"2016-06-27","resultsPosted":"2019-10-23","lastUpdate":"2019-10-23"},"enrollment":738,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Community Acquired Pneumonia"],"interventions":[{"type":"DRUG","name":"lefamulin","otherNames":["BC-3781"]},{"type":"DRUG","name":"Moxifloxacin","otherNames":["Avelox"]}],"arms":[{"label":"lefamulin","type":"EXPERIMENTAL"},{"label":"Moxifloxacin","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia","primaryOutcome":{"measure":"Early Clinical Response (ECR)","timeFrame":"96 hours +/- 24 hours after first dose of study drug","effectByArm":[{"arm":"Lefamulin","deltaMin":336,"sd":null},{"arm":"Moxifloxacin","deltaMin":334,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":155,"countries":["United States","Argentina","Brazil","Bulgaria","Chile","Georgia","Hungary","Latvia","Mexico","Peru","Philippines","Poland","Romania","Russia","Serbia","South Africa","South Korea","Spain","Taiwan","Ukraine"]},"refs":{"pmids":["33964925","31560372"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":368},"commonTop":["Diarrhoea","Nausea","Vomiting"]}}